首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Expert Review Of Anticancer Therapy

Expert Review Of Anticancer Therapy杂志,由Taylor and Francis Ltd.出版,于2001年创刊,Bimonthly,出版语言English,ISSN:1473-7140,E-ISSN:1744-8328。

投稿咨询
Expert Review Of Anticancer Therapy
Expert Review Of Anticancer Therapy
Expert Review Of Anticancer Therapy
SCI SCIE

杂志介绍

JCR分区
Q3
中科院分区
3区
影响因子
3
CiteScore
4.9
期刊收录
SCI、SCIE

Expert Review Of Anticancer Therapy(中文译名:《抗癌治疗专家评论》),ISSN:1473-7140,EISSN:1744-8328,是Taylor and Francis Ltd.出版的国际性学术期刊,创刊于2001年,以Bimonthly形式稳定发行,2026年总发文量约164篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达3,2025年期刊CiteScore为4.9,2025年期刊自引率约3.3%,在中科院期刊分区体系中位列医学大类3区,在所属学科领域具备高学术影响力与国际认可度。Expert Review Of Anticancer Therapy长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期偏慢,4-8周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAItaly、GERMANY (FED REP GER)、France、England、Canada、Belgium等为核心发文国家与地区;UNIVERSITY OF TEXAS SYSTEMUNICANCER、HARVARD UNIVERSITY、INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)、MEMORIAL SLOAN KETTERING CANCER CENTER、FONDAZIONE IRCCS ISTITUTO NAZIONALE TUMORI MILAN、ROYAL MARSDEN NHS FOUNDATION TRUST等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
ONCOLOGY 肿瘤学
3区
否 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
ONCOLOGY 肿瘤学
4区
否 是

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
ONCOLOGY 肿瘤学
4区
否 是

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q3 172 / 333

48.5

学科:ONCOLOGY SCIE Q3 242 / 333

27.48

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 160 / 328

51.4

学科:ONCOLOGY SCIE Q3 209 / 328

36.43


中国学者近期发文

1
A systematic review on clinical pharmacokinetics and pharmacodynamics of antiangiogenic tyrosine kinase inhibitors (TKIs) with high TDM score

Author:Sherazi, Abdul Wasay; Rasool, Muhammad Fawad; Jiao, Zheng; Alqahtani, Faleh

Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2026.2657916

2
The evolving survival landscape in advanced non-small cell lung cancer: an interrupted time series analysi

Author:Ji, Jianwei; Li, Taoying; Li, Zhanwu; Zhou, Jianhua; Qin, Fuhong; Teng, Mengmeng

Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2026.2628946

3
The pricing barrier: cost-effectiveness of Glofitamab for relapsed/refractory DLBCL in China beyond threshold and value-based pricing strategy consideration

Author:Lin, Shen; Wang, Xiangzhen; Yang, Lijing; Luo, Shaohong; Huang, Xiaoting; Weng, Xiuhua; Xu, Xiongwei

Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2026.2630025

4
Integrating liquid biopsies in non-small cell lung cancer diagnosis and management: opportunities and challenge

Author:Lim, Jeong Uk; Oya, Yuko; Fu, Rui; Sooi, Kenneth; Ang, Yvonne L. E.; Soo, Ross A

Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2026.2630026

5
Prognostic factors of undifferentiated embryonal sarcoma of the liver in children: a SEER-based stud

Author:Jin, Qiu; Zhu, Yehang; He, Zhaopeng

Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2025.2612042

6
Effectiveness and cost-effectiveness of first-line versus second-line use of repotrectinib in the treatment of ROS1 fusion-positive advanced NSCL

Author:Huo, Gengwei; Chen, Peng

Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2026.2614708

7
Accuracy of high b-value diffusion-weighted imaging in identifying benign and malignant breast lesions: a systematic review and meta-analysi

Author:Zhang, Jupeng; Wu, Qi; Zhu, Xiqi; Li, Baosheng

Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2025.2510532

8
Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphom

Author:Lin, Yaobin; Shi, Shenghong; Wu, Jiahui; Liu, Shan

Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2025.2517280

9
Epidemiologic and survival analysis for patients with secondary esophageal Cancer: a population-based study and external validatio

Author:Wang, Jie; Zha, Jingyun; Dong, Xiaoliang; Liu, Ping

Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2025.2517883

10
Analysis of the efficacy of paclitaxel combined with bevacizumab intraperitoneal instillation in common gastrointestinal malignant peritoneal effusions and screening of prognostic indicator

Author:Li, Yucong; Mi, Xuguang; Li, Xiaonan; Li, Xiao-Nan; Yang, Ying; Zhou, Ying; Jiang, Xianzhuo; Yu, Yingying; Ni, Zhiqiang; Zhang, Junzi; Lin, Xiuying; Fang, Yanqiu; Hou, Junjie

Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2025.2522251


在线咨询

Expert Review Of Anticancer Therapy

国际简称:EXPERT REV ANTICANC参考译名:抗癌治疗专家评论

年发文量:164 CiteScore:4.9 是否预警:否 Gold OA文章占比:2.11% 研究类文章占比:28.66%

杂志社联系方式:EXPERT REVIEWS, UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, ENGLAND, N3 1QB

Expert Review Of Anticancer Therapy